SK Biopharmaceuticals Signs 48.3 Billion Won Pharmaceutical Supply Contract

On the 24th, SK Biopharmaceuticals announced that it had signed a pharmaceutical supply contract worth 48.3 billion won with its U.S. subsidiary, SK Life Science. This amount is equivalent to 8.8% of its 2024 consolidated sales of 547.6 billion won.

The contract is for supplying products to the subsidiary for the sale of cenobamate, a new antiepileptic drug, in the U.S. market. Because the counterparty is a subsidiary, the transaction is an internal one and will not be reflected as revenue in the consolidated financial statements.

The contract period runs from the 24th through the 26th.